Page 22 - 2019_01-Haematologica-web

Editorials
References
1. Chanan-KhanA,MillerKC,MusialL,etal.Clinicalefficacyoflenalido- mide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24(34):5343- 5349.
2. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118(13):3489-3498.
3. KaterAP,vanOersMHJ,vanNordenY,etal.Feasibilityandefficacyof addition of individualized-dose lenalidomide to chlorambucil and rit- uximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica. 2019;104 (1):147-154.
4. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalido- mide are associated with unacceptable toxicity including life-threaten- ing tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26(15):2519-2525.
5. Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol. 2011;29(9):1175-1181.
6. James DF, Werner L, Brown JR, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the Chronic Lymphocytic Leukemia Research Consortium. J Clin Oncol. 2014;32(19):2067-2073.
7. Strati P, Thompson PA, Keating M, et al. A Phase II Study of the com- bination of lenalidomide and rituximab in patients with treatment- naïVe and relapsed chronic lymphocytic leukemia. Blood. 2016;128(22):4389-4389.
8. BrownJR,AbramsonJ,HochbergE,etal.AphaseIstudyoflenalido- mide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010;24(11):1972-1975.
9. Mato AR, Foon KA, Feldman T, et al. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, fol- lowed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol. 2015;90 (6):487-492.
10. Ujjani C, Wang H, Skarbnik A, et al. A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. Blood Adv. 2018;2(7):762-768.
11. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015;125(21):3357-3359.
12. BarrPM,RobakT,OwenC,etal.Sustainedefficacyanddetailedclin- ical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RES- ONATE-2. Haematologica. 2018;103(9):1502-1510.
13. AhnIE,FarooquiMZH,TianX,etal.Depthanddurabilityofresponse to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357-2366.
14. LeeB-N,GaoH,CohenEN,etal.Treatmentwithlenalidomidemod- ulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011;117(17):3999-4008.
15. StratiP,KeatingMJ,WierdaWG,etal.Lenalidomideinduceslong-last- ing responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013;122(5):734-737.
16. RamsayAG,JohnsonAJ,LeeAM,etal.Chroniclymphocyticleukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437.
17. FecteauJF,CorralLG,GhiaEM,etal.Lenalidomideinhibitstheprolif- eration of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mech- anism independent of functional p53. Blood. 2014;124(10):1637-1644.
18. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-571.
19. Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117-1127.
20. Otahal P, Prukova D, Kral V, et al. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology. 2016;5(4):e1115940.
12
haematologica | 2019; 104(1)